1. GLP-1 landscape in Canada 2026
Canada’s GLP-1 market looks nothing like the American one. Prices are lower thanks to the Patented Medicine Prices Review Board (PMPRB) and a mostly public payer system, but that same regulatory environment has produced tight formularies that exclude weight-loss indications. In 2026 the practical situation for Canadian patients is:
- Health Canada approval: Mounjaro (tirzepatide) is approved by Health Canada for adults with type 2 diabetes as an adjunct to diet and exercise, and separately for chronic weight management in adults with obesity or overweight with a weight-related comorbidity. Both indications carry the same active molecule and same pen presentations.
- Provincial drug plans (OHIP+/ODB in Ontario, BC PharmaCare, Alberta Blue Cross, Quebec RAMQ, plus territorial and Atlantic-province plans) generally list Mounjaro as a restricted or Limited Use benefit for T2DM — never for obesity.
- Private group insurance (Manulife, Sun Life, Canada Life, Great-West/Beneva, Green Shield, Blue Cross plans) varies hugely by employer. Some large employers now include GLP-1 weight-management drugs; many still exclude them via a specific “weight loss” carve-out.
- Cash payers — an estimated majority of Canadian Mounjaro users prescribed for weight loss — buy at pharmacy retail with a valid prescription.
- Cross-border options including personal import from Japan under Health Canada’s 90-day personal-use exemption are increasingly discussed in Canadian patient communities.
2. Mounjaro pricing at pharmacy counters
Retail pricing depends on the pen dose (2.5, 5, 7.5, 10, 12.5, 15 mg), the pharmacy, and any group insurance adjudication. Typical Canadian pharmacy prices for a 4-pen (one-month) supply in mid-2026:
| Dose (monthly) | Cash price | With group insurance* | vs Japan (CAD) |
|---|---|---|---|
| Mounjaro 2.5 mg | CAD $250 – $310 | CAD $150 – $200 copay | ~CAD $220 in Japan |
| Mounjaro 5 mg | CAD $290 – $340 | CAD $170 – $210 copay | ~CAD $280 in Japan |
| Mounjaro 7.5 mg | CAD $310 – $370 | CAD $180 – $220 copay | ~CAD $310 in Japan |
| Mounjaro 10 mg | CAD $330 – $400 | CAD $190 – $240 copay | ~CAD $340 in Japan |
| Mounjaro 15 mg (max) | CAD $380 – $500 | CAD $210 – $280 copay | ~CAD $380 in Japan |
*Group insurance copay assumes a plan that covers Mounjaro for its weight-management indication with roughly 60-80% coinsurance after deductible. Actual copay varies by employer and formulary; many Canadian plans still exclude obesity drugs entirely.
By way of context: the equivalent US cash list price for the same pen sits around USD $1,000-1,200 (~CAD $1,370-1,640) — roughly four times the Canadian retail, thanks to the PMPRB price ceilings for patented medicines.
Canadian pharmacies charge a dispensing fee on top of the drug cost — typically CAD $10-14 per prescription, higher at some Shoppers Drug Mart locations. Ask for a 90-day supply where legal in your province; you pay one dispensing fee instead of three, which shaves CAD $60-80 per year off the total.
3. Coverage province by province
Public reimbursement of Mounjaro is uniform in one direction — no province pays for weight loss — but the T2DM criteria and copay structures differ enough that it’s worth understanding your own plan before assuming you’re on the hook for full cash.
Ontario (ODB / Trillium)
The Ontario Drug Benefit lists Mounjaro as a Limited Use benefit for adults with type 2 diabetes who have inadequate glycaemic control on metformin (HbA1c above threshold) and meet specific clinical criteria. The Trillium Drug Program covers Ontarians without private insurance whose drug costs exceed roughly 4% of household income after a deductible. Weight-loss prescriptions are not reimbursed. OHIP+ (under 25) similarly excludes obesity indications for GLP-1 drugs.
British Columbia (PharmaCare)
BC PharmaCare covers Mounjaro under its Limited Coverage benefit for T2DM patients meeting Special Authority criteria — again, metformin-resistant HbA1c above threshold. Fair PharmaCare income-based deductibles apply. The Plan Z catastrophic tier can help high-cost patients but does not open weight-loss coverage.
Alberta (Alberta Blue Cross)
The Alberta government drug plans (through Alberta Blue Cross) list Mounjaro as a Restricted Benefit for T2DM with Special Authorization. Alberta’s Non-Group Coverage is available to residents without employer insurance and can reduce out-of-pocket cost if the drug is on plan — which for weight-loss prescribing it is not.
Quebec (RAMQ)
RAMQ covers Mounjaro under its Medicament d’exception category for T2DM patients who have failed metformin and meet HbA1c criteria. Quebec residents are automatically enrolled in either RAMQ’s public plan or their employer group plan; the public plan has a monthly deductible plus coinsurance capped annually. Weight-loss prescribing is not eligible for public reimbursement.
Other provinces and territories
Manitoba Pharmacare, Saskatchewan Drug Plan, Nova Scotia Pharmacare, New Brunswick Drug Plan, Newfoundland and Labrador Prescription Drug Program, PEI Pharmacare, and the territorial plans in Yukon, NWT and Nunavut all follow the same broad pattern — Mounjaro listed as an exception or restricted benefit for T2DM, no weight-loss coverage.
The single biggest coverage variable in Canada is not which province you live in — it’s whether your employer’s group plan explicitly includes GLP-1 medications for weight management. In 2025-26 a growing minority of large Canadian employers (some banks, tech firms, universities) added Mounjaro or Wegovy for obesity. If your plan does, out-of-pocket often drops to CAD $180-220 per month. If it doesn’t, your provincial location is largely irrelevant.
4. Ozempic and Wegovy in Canada
Mounjaro is one of three main GLP-1 options a Canadian patient will consider. Quick comparison:
| Drug | Approved for | Cash / month | Public coverage |
|---|---|---|---|
| Mounjaro (tirzepatide) | T2DM + obesity | CAD $250 – $500 | T2DM only (restricted) |
| Ozempic (semaglutide) | T2DM only | CAD $250 – $350 | T2DM only (restricted) |
| Wegovy (higher-dose semaglutide) | Weight management | CAD $400 – $500 | Not covered |
| Saxenda (liraglutide) | Weight management | CAD $450 – $550 | Not covered |
Wegovy launched in Canada in mid-2024 and is now widely stocked at chain pharmacies. It sits at a higher price point than Mounjaro despite similar or slightly weaker clinical weight-loss data. Ozempic is often prescribed off-label for weight loss in Canada, largely because provincial plans occasionally cover it for T2DM whereas Wegovy is always cash. Unlike the US, Canada has essentially no legal grey market for compounded tirzepatide — Health Canada is strict about compounding patented biologics, so almost all Canadian tirzepatide is brand-name Mounjaro.
5. Japan comparison for cash-pay Canadians
Japan is currently the cheapest developed-market source of Mounjaro. The Japanese Ministry of Health, Labour and Welfare (MHLW) sets national drug list prices, and private (self-paid) clinics in Tokyo dispense at prices that flow through the regulated basis:
🇯🇵 Japan — Tokyo private clinics
Why Japanese prices are anchored: The MHLW publishes an official list price for every reimbursed drug. Even at private clinics that operate outside insurance, market competition and patient expectations keep the retail close to that list price — a very different dynamic from Canadian pharmacies pricing off Eli Lilly’s wholesale contract.
For Canadian visitors: A number of Shinjuku and Roppongi clinics run English-language online consultations, verify passport and prescription eligibility, and can dispense a 3-6 month supply for personal use. Hotel delivery within Tokyo is same-day or next-day.
The travel side of the equation:
| Route | Flight time | Return economy (2026) |
|---|---|---|
| Vancouver (YVR) → Tokyo Narita (NRT) | 10 – 11 hours direct | CAD $1,000 – $1,300 |
| Calgary (YYC) → NRT | 11 – 12 hours direct (Air Canada) | CAD $1,100 – $1,400 |
| Toronto (YYZ) → NRT / HND | 13 – 14 hours direct | CAD $1,200 – $1,500 |
| Montreal (YUL) → NRT (via YYZ or non-stop) | 13 – 14 hours | CAD $1,200 – $1,600 |
Direct flights from western Canada are meaningfully shorter and cheaper than eastern-Canada routes; YVR-NRT sub-CAD $1,000 fares appear regularly on ZIPAIR and Air Canada shoulder-season sales. A 3-night Tokyo business hotel stay (APA, Route Inn, Sotetsu Fresa in Shinjuku or Ueno) runs CAD $150-220 per night in 2026, totalling CAD $450-650. Add roughly CAD $200 for food and local transit.
6. Break-even scenarios by city
Whether flying to Japan makes financial sense depends on how many months of supply you need, your home city, and whether your insurance offsets any of the Canadian cash price. Three concrete scenarios:
Local pharmacy vs one Tokyo trip
For a 6-month cash-pay Vancouverite, staying local wins on cost. But extend the horizon:
Local pharmacy vs one Tokyo trip (annual supply)
Where Japan actually pulls ahead is when your cash-pay dose is in the high range or when you can combine treatment with an already-planned Japan trip:
Higher-dose patient piggybacking on a planned Japan trip
Two situations flip the math: (1) you were already planning a Japan trip for tourism or family, in which case the marginal cost of adding a clinic visit is minimal and Japan’s per-month drug price beats Canadian retail; (2) you are on the maximum 15mg dose long-term without insurance coverage, where the CAD $70-120 per month gap starts to compound. For most 6-month first-time Canadian cash-payers who would need to book a dedicated Toronto-Tokyo trip, staying local is cheaper.
7. Health Canada personal import rules
If you do buy Mounjaro in Japan, Health Canada’s personal-use importation policy governs bringing it home. The relevant framework in 2026:
- Quantity limit: Up to a single course of treatment or 90-day supply, whichever is less, of a prescription drug for personal use per entry. For Mounjaro this typically means up to 3 months of pens (12 pens on a weekly regimen).
- Prescription documentation: Carry your Japanese prescription and pharmacy receipt showing your name, the medication, dose, and dispensing date.
- Original packaging: Keep the medication in the original hospital or manufacturer packaging with intact label; loose pens or repackaged product invites additional questioning.
- Personal use only: Cannot be for resale or for use by anyone other than the importer. Cannot be intended for further distribution.
- Cold chain: Mounjaro is refrigerated (2-8°C) until first use and can then be stored at up to 30°C for 21 days. Insulated travel wallets with gel packs are sufficient for the flight home; ask your Japanese clinic for a cold-transport pack.
- Declare at customs: Declare prescription medications on your CBSA declaration if asked. Health Canada’s policy explicitly supports personal-use importation within the 90-day limit.
Practical note: because the personal-import cap is 90 days, the “buy 6 months per trip” approach that works elsewhere is trimmed to 3 months for Canadian residents. Some patients coordinate with a family member or partner who is also prescribed and travelling, doubling the household 3-month allowance into a 6-month effective supply. Each traveller must have their own valid prescription and clinical documentation.
Japanese clinics can legally dispense up to 6 months of a stable-dose Mounjaro prescription in one visit, but Health Canada’s inbound personal-use rule caps imports at 90 days. If you buy 6 months in Japan, you cannot carry all of it back on one flight. Options: (a) take only 3 months on your first return; (b) have a second traveller carry the remaining 3 months if legally prescribed to them; (c) coordinate a second trip. Do not attempt to ship the balance internationally — international pharmaceutical shipping to Canada by an individual is separately regulated and generally not permitted without an import licence.
8. Provincial vs private vs Japan decision
Putting it all together, a rough decision framework for a Canadian patient in 2026:
Provincial plan pathway — worth pursuing if:
- You have type 2 diabetes and meet HbA1c / prior-therapy thresholds. Ask your family doctor about a Special Authority (BC), Limited Use (Ontario), Medicament d’exception (Quebec), or Special Authorization (Alberta) request for Mounjaro.
- You are in Quebec on the public RAMQ plan (annual out-of-pocket cap can help chronic users) and qualify on the T2DM indication.
- Do not expect provincial coverage for weight-loss indication — this remains extremely rare across every Canadian province in 2026.
Private insurance pathway — worth pursuing if:
- Your employer plan lists Mounjaro or Wegovy on its obesity or weight-management formulary. Log in to your plan portal and search the drug name — it’s explicit if covered.
- You can escalate an appeal or ask HR whether your employer’s formulary would consider adding GLP-1 obesity coverage. Larger employers have been reviewing this actively.
- Copay typically lands at CAD $180-220/month if coverage exists.
Cash-pay Canadian pharmacy — the default when:
- You are prescribed for weight management and don’t have private coverage.
- You want simplicity and continuity of care with a local family physician or obesity-medicine specialist.
- Total treatment horizon is 6-12 months at low-mid dose. In this range Canadian cash-pay is competitive with Japan once travel is factored in.
Japan trip pathway — makes sense when:
- You are already planning a trip to Japan for tourism, business, or family. Marginal cost of adding a clinic visit is tiny and Japan wins on per-month price.
- You are on 15mg maintenance long-term without insurance coverage — the per-month savings compound faster.
- You value multi-month prescription visibility (6 months on one prescription in Japan even if you only carry 3 months home per trip).
- You have a travelling partner or family member also prescribed, doubling the personal-import quota per trip.
Wherever you source Mounjaro, remember it is a supported treatment — not a standalone weight-loss product. The trial data supporting Mounjaro (SURMOUNT-1, SURMOUNT-2) all combined the medication with structured diet and physical-activity guidance. Whether you fill your prescription in Vancouver, Montreal, or Tokyo, the outcomes depend as much on the nutrition and follow-up around the drug as on the drug itself. Prioritise a clinic that offers integrated lifestyle support, not one that only optimises for the lowest per-pen price.
9. FAQ
How much does Mounjaro cost in Canada in 2026?
Cash-pay Mounjaro in Canada typically runs CAD $250-350 per month for the starting 2.5mg dose, rising toward CAD $380-500 at the 15mg maintenance dose. Patients whose employer group insurance covers Mounjaro for obesity often pay a copay of roughly CAD $180-220 per month. Provincial drug plans (OHIP+, MSP, RAMQ, Alberta Blue Cross) cover Mounjaro only for type 2 diabetes with special authorization — weight-loss indication is not publicly funded anywhere in Canada in 2026.
Does OHIP cover Mounjaro for weight loss in Ontario?
No. Neither OHIP nor the Ontario Drug Benefit covers Mounjaro for weight loss. Mounjaro appears on the ODB formulary as a Limited Use benefit for type 2 diabetes only, requiring documented prior metformin therapy and specific HbA1c thresholds. OHIP+ (under 25) applies the same restriction. Weight-loss prescriptions are cash-pay or must go through a private group insurance plan.
Does Quebec RAMQ cover Mounjaro?
RAMQ lists Mounjaro under its Medicament d’exception category for adults with type 2 diabetes who meet specified HbA1c and prior-therapy criteria. Weight-loss use is not reimbursed. Quebec residents must be enrolled in either RAMQ or a qualifying private group plan; RAMQ has annual out-of-pocket caps that can benefit chronic users.
Is it cheaper to fly from Canada to Japan for Mounjaro?
For most 6-month first-time cash-payers, no — the added flight and hotel usually outweigh the per-month savings. Where Japan wins is when you (a) are already travelling to Japan for other reasons and just add a clinic visit, (b) are on 15mg maintenance dose long-term without private insurance, or (c) can coordinate with a travelling partner who is also prescribed and can double the personal-import quota. See the break-even scenarios above for city-specific math.
Can I legally bring Mounjaro back to Canada from Japan?
Yes, within limits. Health Canada permits personal-use importation of a single course of treatment or a 90-day supply of a prescription drug, whichever is less. For Mounjaro this typically means up to 3 months of pens per traveller per entry. Keep medication in original manufacturer packaging with intact label, carry your Japanese prescription and receipt, and declare at customs if asked.
What is the difference between Mounjaro, Ozempic and Wegovy in Canada?
Mounjaro (tirzepatide, Eli Lilly) is Health Canada approved for type 2 diabetes and for chronic weight management. Ozempic (semaglutide, Novo Nordisk) is approved only for type 2 diabetes, though it’s widely used off-label for weight loss. Wegovy (higher-dose semaglutide) launched in Canada in 2024 for weight management at roughly CAD $400-500 per month cash. Mounjaro tends to have the strongest weight-loss data at maintenance dose; Wegovy has the longer real-world track record for obesity; Ozempic sometimes has provincial coverage for T2DM that Mounjaro or Wegovy lack.
Will Canadian Mounjaro prices go down in 2026-27?
Modest downward pressure is possible as the PMPRB continues reviewing GLP-1 pricing, but Eli Lilly’s Canadian list price has been stable and biosimilar tirzepatide is not expected until late in the decade. Public formulary coverage for the obesity indication is unlikely to expand quickly given provincial budget pressures. Expect roughly today’s cash-pay range through the medium term.
Sources & further reading
- Health Canada — Personal importation of health products policy
- Patented Medicine Prices Review Board (PMPRB) — Annual reports on patented drug pricing in Canada
- Ontario Drug Benefit Formulary — Limited Use criteria for Mounjaro (tirzepatide)
- BC PharmaCare — Special Authority criteria for tirzepatide
- RAMQ — Liste des medicaments d’exception
- Alberta Blue Cross — Drug Benefit List and Special Authorization criteria
- Eli Lilly Canada — Mounjaro product monograph
- KFF Health System Tracker — Prices of drugs for weight loss in the US and peer nations